Hemophilia
Precise sample timing, standardized coagulation testing, inhibitor monitoring, and traceable sample logistics — Omega ecosystem supports hemophilia clinical trials through an integrated model.
Hemophilia Clinical Trial Support
In hemophilia studies, the value of laboratory data comes not only from performing the test, but also from accurate sample timing, standardization of coagulation parameters, inhibitor monitoring, and proper management of the patient journey.
Omega ecosystem supports Hemophilia A and Hemophilia B studies through an integrated model covering central laboratory services, genetic analysis, sample management, and home-sampling processes.
From coagulation testing to inhibitor monitoring, genetic confirmation, and sample logistics, we help sponsors build traceable, protocol-aligned workflows for hemophilia studies.
Why is a Specialized Laboratory Approach Required?
Critical laboratory outputs in hemophilia studies are often highly time-sensitive. Parameters such as Factor VIII (FVIII) and Factor IX (FIX) activity, inhibitor development, PK/PD evaluations, post-bleeding episode sampling, and response to prophylaxis require strict adherence to protocol-defined time windows.
Guidelines from the World Federation of Hemophilia also emphasize the importance of genetic evaluation, extended half-life factor products, and emerging treatment approaches in hemophilia management.
Comprehensive Hematology Support
Coagulation & Safety Laboratory Support
In hemophilia studies, routine safety laboratory assessments and coagulation testing should be planned in an integrated manner. Parameters such as:
- Factor activity measurements (FVIII, FIX)
- Activated partial thromboplastin time (aPTT)
- Prothrombin time (PT)
- Complete blood count and biochemistry
are structured according to protocol-defined time points to ensure comparable data flow between clinical events, treatment administration, and laboratory results.
Inhibitor Monitoring
Inhibitor development is one of the most critical complications in hemophilia treatment. The Centers for Disease Control and Prevention (CDC) recommends that individuals with hemophilia or type 3 von Willebrand disease who use factor concentrates should be tested for inhibitors at least once a year.
In clinical trials, inhibitor testing schedules, sample stability, laboratory methodology, and reporting language should be standardized from the outset.
Pharmacokinetics & Pharmacodynamics
PK/PD sampling can be critical in studies involving factor replacement products, extended half-life factors, non-factor therapies, and gene therapy.
- Pre-dose and post-dose time points
- Trough levels and peak levels
- Long-term response monitoring
Genetic & Molecular Testing
Hemophilia A and Hemophilia B are inherited bleeding disorders associated with the F8 and F9 genes, respectively.
Genetic confirmation can be valuable for patient stratification, family history assessment, variant interpretation, and eligibility evaluation in certain study designs. Integration with Omega Genetik can be particularly emphasized in this context.
Sample Logistics & Home Sampling
In hemophilia patients, factors such as frequent visit burden, pediatric populations, limited mobility, or time-sensitive sampling following bleeding episodes make home sampling and mobile team models especially valuable. Our integrated approach ensures traceable, protocol-aligned workflows from sample collection through laboratory analysis.
Coagulation Testing Coordination
Protocol-Aligned Sampling
Sampling and reporting workflows structured for factor activity, coagulation parameters, and safety laboratory outputs.
Integrated Analysis
Coagulation testing coordinated with safety assessments, PK/PD sampling, and genetic confirmation workflows.
Traceable Reporting
Standardized reporting with complete traceability from sample collection to laboratory result delivery.
Application Scenarios in the Omega Ecosystem
How the Omega ecosystem delivers integrated support for hemophilia studies\u2014from coagulation testing to genetic confirmation and home sampling.
HelixLab
Coagulation & Factor Activity
Protocol-aligned FVIII/FIX activity assays (one-stage and chromogenic), aPTT, PT/INR, thrombin generation assays, and routine safety panels structured by defined time windows.
Omega Genetics
F8/F9 Variant Analysis
Full-length F8 gene sequencing including intron 1 and intron 22 inversion detection; F9 variant identification and inhibitor risk genotyping (HLA class I/II profiling).
Omega Biorepository
PK/PD Plasma Banking
Serial plasma aliquots at pre-dose, peak, and trough time points stored at -80\u00b0C for retrospective pharmacokinetic modeling and extended half-life product comparisons.
Omega Care
Home Bleeding Episode Sampling
Rapid-response mobile teams for time-sensitive post-bleed and pre-dose sampling at home; pediatric visit reduction through scheduled home factor activity monitoring.
Omega Bio
Bethesda Assay Standardization
Kit-based Nijmegen-modified Bethesda assay harmonization for inhibitor detection; lot-to-lot consistency ensuring reliable cross-site inhibitor incidence comparisons.
Animal Facility
Hemophilia A/B Animal Models
F8-knockout and F9-knockout mouse models for preclinical evaluation of factor replacement products, extended half-life therapeutics, and gene therapy candidates.
Build Traceable Hemophilia Study Workflows
Partner with Omega ecosystem for integrated hemophilia clinical trial laboratory support.
Talk to Our Experts